Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.
暂无分享,去创建一个
B. Chauffert | T. Conroy | M. Ychou | M. Ducreux | J. Pierga | D. Malka | A. Adenis | E. François | E. Boucher | C. Montoto-Grillot | J. Ichante | J. Pignon